Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 8 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 11857697

    Compositions and methods for obtaining 3-dimensional lung-like epithelium and related uses thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  2. US 11859190

    Methods and compositions for regulation of transgene expression

    Sangamo Therapeutics, Inc. · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  3. US 11851680

    Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

    Precision BioSciences, Inc. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  4. US 11851655

    Compositions and methods for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  5. US 11844765

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  6. US 11845937

    RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  7. US 11845965

    Regulation of gene expression using engineered nucleases

    Sangamo Therapeutics, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  8. US 11845778

    Prefusion PIV F immunogens and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  9. US 11840688

    Compositions and methods for inhibiting gene expression of Hif2alpha

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  10. US 11840686

    Modulation of prekallikrein (PKK) expression

    Ionis Pharmaceuticals, Inc. · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  11. US 11840690

    Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAs targeting the expanded hexanucleotide repeat

    The Board of Regents of the University of Texas System · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  12. US 11839631

    Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

    United Therapeutics Corporation · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  13. US 11833211

    Methods of suppression and treatment of disease comprising administering bicycle peptide ligands specific for EphA2

    BicycleTx Limited · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  14. US 11834688

    Ligase fusion proteins and application thereof

    GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  15. US 11833168

    Compounds and methods for increasing STMN2 expression

    Ionis Pharmaceuticals, Inc. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  16. US 11833221

    Oligomeric compounds for reducing DMPK expression

    Ionis Pharmaceuticals, Inc. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  17. US 11834660

    Compositions for modulating Ataxin 2 expression

    Ionis Pharmaceuticals, Inc. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  18. US 11826392

    Purification method of fungal cell wall composition

    HONG SHENG PRECISION BIOTECH CO., LTD. · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted
  19. US 11827691

    Serpin fusion polypeptides and methods of use thereof

    Inhibrx, Inc. · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted
  20. US 11819554

    Compositions and methods for modulating FMR1 expression

    Fulcrum Therapeutics, Inc. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  21. US 11807661

    Antibody fusion protein and related compositions for targeting cancer

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  22. US 11806318

    Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted
  23. US 11786554

    Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  24. US 11788077

    Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome

    Precision BioSciences, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted